Biomedical Engineering Reference
In-Depth Information
Henry S, McAllister DV, Allen MG, Prausnitz MR, (1998). Microfabricated
microneedles: A novel approach to transdermal drug delivery.
J. Pharm.
Sci.
, 87:922-925.
Hindle M, (2004). Soft mist inhalers: A review of current technology. The
Drug Delivery Companies Report, autumn/winter,
PharmaVentures,
pp.31-34.
Hochrainer D, Hölz H, (2001). Comparison of the velocities of clouds
delivered from Respimat
®
soft mist inhaler and metered dose inhalers.
J.
Aerosol. Med.,
14:386P1-386P5.
Ismail NE, Chrystyn H, (2004). The relative bioavailability of salbutamol to
the lungs from a U22 MicroAir nebuliser.
J. Pharm. Pharmacol
., 56:S39.
Jauernig J, Ohl S, Luber M, Keller M. Differences in results obtained with the
next generation impactor (NGI) for Pulmicort
®
suspension and according
to the CEN-standard EN-13544-1 for a NaF-solution.
Drug Delivery to the
Lungs
, XIV, (2003), pp.41-44.
Jones LS, Kaufmann A, Middaugh CR, (2005). Silicone oil induced
aggregation of proteins.
J. Pharm. Sci
., 94:918-927.
Kelly JA, Molyneux PD, Smith SA, Smith SE, (1989). Relative bioavailability
of pilocarpine from a novel ophthalmic delivery system and conventional
eyedrop formulations.
Br. J. Ophthalmol.,
73:360-362.
Kishida M, Okada M, Izawa M, Shimoda M, Saito M, Takeshita Y, Koshibu
T, Nakazono H, Suzuki I, Shinomiya N. Aoki T, (2003). Clinical
examination of miniature mesh nebulizer Micro Air
®
.
Allergy Immunol.,
10:136-140.
Kublik H, Vidgren MT, (1998). Nasal delivery systems and their effect on
deposition and absorption.
Adv. Drug Del. Rev
., 29:157-177.
Ledermüller R, Stangl R, Knoch M. Nebuliser technology.
Business Briefing:
Global Healthcare, Touch Briefings,
(2003), pp 1-4.
Levin G, Gershonowitz A, Sacks H, Sherman A, Rudaey S, Zivin I, Philip M,
(2005).
Transdermal
delivery
of
growth
hormone
through
RF-
microchannels
. Pharm. Res
., 22:550-555.
Lewis RA, (1983). Nebulisers for lung aerosol therapy.
Lancet
, 2:849.
Lteif AN, Schwenk WF, (1999). Accuracy of pen injectors versus insulin
syringes in children with type 1 diabetes.
Diabetes Care,
22:137-140.
Luthringer R, Sheldrake CD, Flint A, Djupesland PG. Intranasal sumitriptan
powder delivered with a new device is as effective as 6 mg SC
sumatriptan in preventing glyceryltrinitrate (GTN) challenge induced EEG
changes in migraineurs. American Academy of Neurology, April 2008.
